David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.
While the potential for fundus images is recognized, the methodology and clinical application must be improved.
According to researchers at Johns Hopkins Children’s Center, AI-driven cameras take images of the back of the eye and require no eye drops can be used to close care gaps.
According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.
New technology may shift the diagnostic paradigm
A recent study found that despite worldwide reports of ocular inflammatory events being reported after patients received COVID-19 vaccinations, a low amount has been reported in the UK.
Physicians note the impact of prism lenses can be life-changing for patients.
Genetic testing is proving to be an evolving technology for ophthalmologists.
According to the company, the research is being conducted in collaboration with London-based Imperial College Healthcare NHS Trust.
Authors believe that PVI and PHMB are not associated with postoperative ocular irritation.
Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.
The new contact lenses contain micro-sensors which monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analyzed by an ophthalmologist and a diagnosis given.
The recall is “due to potential safety concerns after FDA investigators found insanitary conditions.”
Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.
The app is a tool aimed at allowing patients to measure their visual acuity at home by themselves.
According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.
Among 85 trials representing 34 ophthalmic drugs, a study revealed more than of ophthalmology 75% of trials associated with FDA drug approvals conflated sex and gender, while more than two-thirds of these trials lacked any sex- and gender-based data analyses.
A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.
Researchers are unveiling results show previously unknown inherited genetic variants that contribute to primary open-angle glaucoma, the most common form of the disease.
Siloam Vision and Orbis team up to develop infrastructure to save the vision of premature infants.
The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.
Kamuvudines are a new class of inflammasome inhibitor drugs as therapies for prevalent, degenerative diseases. The trial is evaluating SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor.
Legislators in New Hampshire, Missouri, West Virginia are among states considering amendments to the regulation of optometry.
Bonnie An Henderson, MD, previews the EnVision Summit 2024, scheduled for February 16 to 19 in Puerto Rico, highlighting its family friendly atmosphere, diverse specialty coverage, and new sessions on leadership and health equity.
Consensus, awareness, and a CVI registry: top priorities of the trans-NIH event
Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.
According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.
Swiss Ophthalmology Innovation (Sophi) is a phaco technology providing mobility, simplicity, and safety within the operating field.
